These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15632877)

  • 1. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
    Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P; Tognoni G; Cohn JN
    J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
    Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
    Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
    J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN
    Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
    J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
    Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
    Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
    Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
    Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
    Anand IS; Kuskowski MA; Rector TS; Florea VG; Glazer RD; Hester A; Chiang YT; Aknay N; Maggioni AP; Opasich C; Latini R; Cohn JN
    Circulation; 2005 Aug; 112(8):1121-7. PubMed ID: 16103233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
    Krum H; Latini R; Maggioni AP; Anand I; Masson S; Carretta E; Ingrillì F; Pettinati G; Glazer R; Tognoni G; Cohn J
    Int J Cardiol; 2007 Jun; 119(1):48-53. PubMed ID: 17049646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
    Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.